Typically, Novartis is known for making larger partnership deals. This time around it chose to go for a straight buyout to get its hands on Endocyte's Lu-PSMA-617 clinical product. Under the terms of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Novartis has agreed to acquire Myricx Bio, a London-based developer of next-generation antibody-drug conjugates (ADCs), for up to $1.5 billion in a deal designed to bolster the buyer’s oncology ...

By Bhanvi Satija LONDON, Oct 23 (Reuters) - Swiss drugmaker Novartis' drug Kisqali helped extend survival for women with a ...

Emmy-winning actress Katherine LaNasa, 59, who plays compassionate charge nurse Dana Evans on HBO Max's The Pitt, is using ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novartis received FDA approval for Pluvicto in PSMA positive ...

The new FDA nod represents Pluvicto’s first foray into an earlier manifestation of prostate cancer, which typically progresses to the castration-resistant form within 20 months. (Sedat Suna/Getty ...

Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact across multiple solid tumor settings Basel, July 6, 2026 - Novartis today ...